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Abstract Research in animals and humans has associated
Alzheimer’s disease (AD) with decreased cerebrospinal
fluid levels of insulin in combination with decreased
insulin sensitivity (insulin resistance) in the brain. This
phenomenon is accompanied by attenuated receptor
expression of insulin and insulin-like growth factor,
enhanced serine phosphorylation of insulin receptor sub-
strate-1, and impaired transport of insulin across the blood-
brain barrier. Moreover, clinical trials have demonstrated
that intranasal insulin improves both memory performance
and metabolic integrity of the brain in patients suffering
from AD or its prodrome, mild cognitive impairment.
These results, in conjunction with the finding that insulin
mitigates hippocampal synapse vulnerability to beta amy-
loid, a peptide thought to be causative in the development
of AD, provide a strong rationale for hypothesizing that
pharmacological strategies bolstering brain insulin signal-
ing, such as intranasal administration of insulin, could have
significant potential in the treatment and prevention of AD.
With this view in mind, the review at hand will present
molecular mechanisms potentially underlying the memory-
enhancing and neuroprotective effects of intranasal insulin.
Then, we will discuss the results of intranasal insulin
studies that have demonstrated that enhancing brain insulin
signaling improves memory and learning processes in both
cognitively healthy and impaired humans. Finally, we will
provide an overview of neuroimaging studies indicating
that disturbances in insulin metabolism—such as insulin
resistance in obesity, type 2 diabetes and AD—and altered
brain responses to insulin are linked to decreased cerebral
volume and especially to hippocampal atrophy.
1 Introduction
Alzheimer’s disease (AD) is a pathophysiological process
leading to, but starting long before dementia emerges [1].
AD affected 35.6 million people worldwide in the year
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2012 [2]. Due to aging of the human population in devel-
oped and developing societies, it is expected that this
number will double by the year 2030 and more than triple
by 2050 [3]. In the US alone, the cost of caring for indi-
viduals with AD is expected to rise from 200 billion dollars
in 2012 to 1.1 trillion in 2050 [4]. Thus, AD and related
forms of dementia have become one of the most severe
socioeconomic and medical burdens impacting modern
society [5]. Even small advances in therapeutic strategies
could lead to a delay in the onset and progression of AD
and would significantly reduce this burden.
Alterations in brain insulin metabolism have been sug-
gested as one pathophysiological factor underlying this
neurodegenerative disorder [6–8]. In line with this
hypothesis, AD patients show reduced brain insulin
receptor sensitivity [9, 10], hypophosphorylation of the
insulin receptor and downstream second messengers such
as the insulin receptor substrate-1 [10, 11] and attenuated
insulin and insulin-like growth factor receptor expression
[11]. Furthermore, reduced cerebrospinal fluid (CSF)
insulin levels have been observed in moderate and severe
cases of AD [12]; however, this research is not conclusive.
Other studies have demonstrated either normal [13] or
increased CSF insulin levels in AD patients [14]. More-
over, in the only existing study measuring CSF insulin
levels in AD brains that explicitly used age-matched
healthy control brains, normal levels of the hormone were
detected [15]. Similar findings have been reported for
insulin and insulin-like growth factor receptor expres-
sion—evidence for attenuated levels [11], but also for
normal or increased levels exists [10, 15]. Figure 1 pro-
vides an overview on the putative role of insulin in AD
pathology.
As enhanced brain insulin signaling improves memory
processes in cognitively healthy humans [16–18] and
possesses neuroprotective properties [19, 20], increasing
brain insulin concentrations in AD patients could be a
promising approach to prevent or slow the progression of
this devastating disease. Thus, it is not surprising that
intranasal administration of insulin in AD patients enabling
insulin to directly access the brain [21, 22] was recently
selected by the National Institute of Health (NIH) as one of
two therapeutic strategies receiving substantial funding as
part of the National Alzheimer’s Plan in the US. This plan
is a federal initiative to find an effective way to prevent or
treat AD by 2025 [23].
In this review we will explore the underlying neural
network and possible molecular mechanisms that mediate
the protective effects of insulin in the human brain. Also,
we aim to provide an overview of the concept and current
findings regarding the use of intranasal insulin to improve
memory function in healthy and cognitively impaired
humans.
2 Role of Insulin in Normal Brain Function
In healthy participants, intranasal insulin administration
over the course of 8 weeks improved performance on a
declarative memory task (delayed recall) based on a word
list that had to be remembered acutely and 1 week later
[16]. This enhancing effect on declarative memory, a hip-
pocampus-dependent function [24], was amplified when
insulin aspart, a fast-acting insulin analog, was used [25].
More recent studies have provided evidence that even a
single acute dose of insulin (160 IU) enhances hippocam-
pus-dependent memory processes, as measured by both
spatial and working memory tasks [18, 26]. Furthermore,
verbal working memory, a capacity that relies on activation
of the frontal cortex [27], is improved after a single
intranasal application of insulin [18].
3 Intranasal Insulin Improves Memory Function
in Cognitively Impaired Humans
A single dose of intranasal insulin acutely improved
memory in memory-impaired older adults with AD or mild
cognitive impairment (MCI) and also improved memory
and cognitive function with multiple treatments of patients
with AD or MCI [28]. Insulin was effective in improving
performance on a verbal memory test in a group of AD and
MCI patients; however, within this group subjects carrying
the APOEe4 allele, a strong genetic predictor for AD,
showed poorer recall following insulin administration
compared to patients that do not posses this allele and
healthy controls [28]. Further work from the same group
suggests a differential dose–response curve to intranasally
applied insulin, such that word and story recall was
enhanced by a relatively low dose of insulin in patients that
do not posses the APOEe4 allele while APOEe4 patients
demonstrated a relative decline in memory [29]. Additional
research indicated that attention and functional status (e.g.,
orientation, judgment, social interactions, home activities,
personal care, speech/language) of this patient group was
enhanced by insulin [30].
In the first pilot clinical trial on the use of intranasal
insulin therapy in 64 MCI and 40 AD patients, participants
received either placebo, 20 IU of insulin, or 40 IU of
insulin administered with a nasal spray over the course of
4 months. The main outcome measures were delayed story
recall, Dementia Severity Rating Scale, Alzheimer Dis-
ease’s Assessment Scale-cognitive subscale and Alzhei-
mer’s Disease Cooperative Study-activities of daily living
scale. Subsets of participants further underwent lumbar
puncture and a positron emission tomography (PET) study
before and after treatment. The between-subject compari-
son showed that intranasal insulin improved delayed
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memory and cognitive function, and, importantly, also
preserved the functional ability of the patients as estimated
by caregiver ratings, suggesting that the improvements
were clinically relevant. Based on PET findings, the
authors also provided direct evidence for a higher 18F
fluorodeoxyglucose uptake in the parietotemporal, frontal,
precuneus and cuneus regions of the CNS following
intranasal insulin compared to placebo administration,
linking the enhancement in functioning to processes in
those brain areas [31]. As indicated by Schio¨th et al. [32],
this clinical trial employed a relatively low sample size, the
treatment period was comparatively short, and, in absolute
terms, the improvements were moderate. Nevertheless, the
improvements in episodic memory were still present 2
months after cessation of treatment.
A meta-analysis investigating structural brain changes in
patients with MCI revealed convergent gray matter atrophy
in the bilateral amygdala and hippocampus, extending to
the left medial temporal pole, thalamus and bilateral pre-
cuneus [33]. Significant reduction of gray matter volume in
perirhinal and hippocampal regions and a functional
decline in inferior parietal lobules and precuneus has also
been established in patients during the conversion from
amnestic MCI to AD, as well as patients with early AD [34,
Fig. 1 Overview of the role of
insulin and insulin sensitivity in
the pathology of Alzheimer’s
disease
Insulin and the Brain 507
35]. Taken together, these imaging studies reveal brain
atrophy in the hippocampal region, which seems to be the
most consistent structural marker of the associated cogni-
tive deterioration and a strong predictor of AD.
In conclusion, the present research is promising because
small but consistent improvements of cognitive memory
processes induced by insulin have been discovered [36];
however, further clinical trials are needed to assess the
clinical relevance of intranasal insulin in the treatment of
cognitive disorders.
4 Disturbances in Insulin Signaling and Glucose
Metabolism are Linked to Altered Brain Responses
to Insulin
Impaired insulin sensitivity of the brain and in the
periphery of the human body, so-called insulin resistance,
is associated with cognitive decline and smaller total brain
size [37]. Further, in the insulin-resistant state reduced
spontaneous (task-independent) cortical activity has been
observed as reflected by decreased theta band activity, a
low-frequency EEG component of which is positively
related to memory performance [38]. Supporting this view,
biochemical analysis of brains of AD patients revealed
central nervous system (CNS) insulin desensitization,
which was correlated with the magnitude of cognitive
impairments [10, 39]. Disturbances in glucose and energy
metabolism and brain insulin signaling are therefore con-
sidered a pathological hallmark of AD [7, 40].
In a recent 18F PET study, insulin resistance was also
associated with a pattern of reduced cerebral glucose
metabolism in frontal, temporo-parietal and cingulate
regions in cognitively intact adults with prediabetes or type
2 diabetes [41]. Bearing in mind that such patterns of
hypometabolism have likewise been observed in patients
with MCI and AD [42, 43] and that diabetes is a risk factor
for AD [44], screening for insulin resistance may provide a
relatively low-cost, non-invasive means for identifying
adults at risk to develop the disease.
In a voxel-based morphometric (VBM) study in a large
population of healthy elderly subjects (at the age of
75 years), Benedict and colleagues [37] were able to show
that the HOMA-IR score, a measure of peripheral insulin
resistance, was negatively correlated with verbal fluency
performance, total brain size and regional gray matter
volume in bilateral areas of the middle and superior tem-
poral gyri, i.e., typical speech-processing areas. Willette
et al. [45] confirmed this finding for middle-aged healthy
subjects (at the age of 58 years). Further results from a
structural imaging study in healthy participants point
toward an inverse correlation of peripheral insulin resis-
tance with total cerebral volume, but also with executive
functions, verbal and visuospatial memory [46]. The
HOMA-IR score of patients at risk for AD was negatively
associated with right and total hippocampal volume as well
as overall cognitive performance, and verbal and non-
verbal memory tests [47]; however, unlike in the previ-
ously mentioned study involving MCI patients, this corre-
lation was not influenced by the presence of the APOEe4
allele. In conclusion, these studies shed light on anatomical
correlates of healthy and cognitively impaired individuals
and provide evidence for diminished total brain and hip-
pocampal volume with higher insulin resistance rates.
Using resting-state imaging methods the activity of the
brain in the absence of an external stimulus or task is
assessed. Here, spontaneous fluctuations that are useful to
explore the brain’s functional organization are of interest.
The most important resting-state network is the default-
mode network (DMN), which is activated when we are
awake and at rest and is deactivated during goal-oriented
behavior. The DMN is an interconnected system of medial
prefrontal, medial temporal, posterior cingulate, medial,
lateral and inferior parietal cortical areas as well as the
ventral precuneus. The resting-state activity and also the
degree of structural and functional connectivity of the
resting-state network is a biomarker for cognitive function
and aging. In women at risk for AD, elevated plasma
insulin levels have been associated with a decrease of
connectivity between the DMN areas prefrontal cortex and
hippocampus, pointing toward an involvement of the
connectivity of these brain areas in AD pathology [48].
It has further been revealed in magnetoencephalography
(MEG) studies in cognitively healthy subjects that intra-
nasal insulin modifies the brain network during the resting
state by changing the characteristic path length in the theta
band [49]. The theta band or theta rhythm is a frequency
component that tends to appear during rest. The authors
considered this phenomenon an increase in communication
efficiency, particularly between brain areas involved in
satiation and homeostatic control of eating behavior caused
by the rise in CSF insulin level. In addition, insulin mod-
ulated intrinsic cortical activity in hypothalamic and
orbitofrontal cortex areas [50], two brain areas involved in
the modification of reward during food consumption.
Whereas intranasally applied insulin had no effects on
basal cerebral blood flow (CBF) or task-induced CBF after
visual stimulation [51], a decrease of the blood oxygen
level-dependent (BOLD) response after visual stimulation
with food pictures was found in several areas of the fronto-
temporal network [52]. The authors of the latter studies
primarily attribute their findings to the importance of
insulin signaling during processes related to food con-
sumption and the location of food sources. However, these
findings do not allow conclusions regarding the effect of
intranasal insulin on the connectivity strength of brain
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components affected in the early stages of AD, such as the
hippocampus.
Since the homeostatic system heavily depends upon the
sense of smell and, interestingly, the brain regions first
affected by AD are those involved in the sense of smell
(e.g., olfactory bulb, entorhinal cortex, hippocampus) [53],
it seems reasonable that distortions in olfactory perfor-
mance are experienced very early in the progression of the
pathology [54]. This hypothesis is further supported by
research in the rat model proving that ablation of the
olfactory bulbs leads to a deficiency in spatial memory and
higher levels of beta amyloid in the hippocampal areas
[55]. Olfactory performance scores are hence considered
behavioral markers for an early diagnosis of AD [56] or
other neurodegenerative disorders. As olfactory informa-
tion enters the human cortical areas without a thalamic
relay, they have direct access to brain areas responsible for
emotional processing (amygdala) and memory formation
(hippocampus). Consequently, odors are potent cues for
memory consolidation. Since the brain regions involved in
olfactory and memory processes both contain high amounts
of insulin receptors [57, 58], future studies should elaborate
whether the memory-enhancing effects of insulin could be
potentiated by presenting associated odor cues.
5 Molecular Mechanisms of the Protective Actions
of Insulin in the Brain
Although defective brain insulin signaling is increasingly
considered an important feature of AD pathology, the
biological mechanisms of brain insulin resistance in AD
have just recently started to be unraveled. Initial molecular
clues came from studies demonstrating that amyloid beta
oligomers (AbOs), toxins that accumulate in brains of AD
patients and instigate synapse damage [59], bind to hip-
pocampal neurons and trigger the removal of insulin
receptors from the plasma membrane [20, 60, 61]. But-
tressing the clinical relevance of these findings, Moloney
and co-workers [62] verified this phenomenon. AbOs also
alter neuronal insulin receptor function, and this effect
seems to be an important aspect of the overall synaptic/
neuronal pathology induced by AbOs [39, 60, 61].
More recently, evidence linking pathogenic mechanisms
triggered by AbOs in the AD brain to mechanisms present
in metabolic diseases has emerged [39, 63, 64]. In type 2
diabetes and obesity-related insulin resistance, activation of
c-Jun N-terminal kinase (JNK) leads to IRS-1 serine
phosphorylation (IRS-1pSer), resulting in peripheral insu-
lin resistance [65, 66]. Similarly, AbOs induce activation
of the JNK pathway and IRS-1 inhibition in cultured hip-
pocampal neurons [39, 63] as well as within the brain of
mice and monkeys [39]. Likewise, post-mortem brains of
AD patients show abnormal distribution of IRs [62],
increased serine phosphorylation of IRS-1 [10, 61] and
reduced cytosolic and/or membrane levels of PI3K and
PI3K-dependent kinase 1 (PDK1) [62, 67]. AD brains
further display elevated levels of phosphorylated JNK [39],
which is known to counteract peripheral insulin signaling
[39, 68]. In conjunction, these studies suggest that the
relationship between CNS insulin impairment and AbO
accumulation in the brain is rather complex and should be
evaluated in future studies.
The discovery of a molecular parallel between defective
brain insulin signaling in AD and peripheral insulin sig-
naling dysfunction in diabetes [10, 39] provides a rationale
for using anti-diabetes agents as novel therapeutics in AD.
Supporting this view, a treatment with the glucagon-like
peptide 1 (GLP-1) analog liraglutide (commonly used in
the treatment of diabetes) leads to an amelioration of
insulin resistances in the brains of AD patients and a mouse
model of AD [69] and positive effects on neuropathology
and cognition in the mouse model [70]. The next important
step is to understand if and how stimulation of insulin
signaling in the brain might facilitate neuroprotection,
thereby preserving normal brain functioning. As touched
on previously, insulin’s actions seem to be important for
proper hippocampal function, a region equipped with
insulin receptors [71] that is profoundly involved in the
acquisition, consolidation and recollection of memories.
In cell culture experiments using highly differentiated
cultures of rat hippocampal neurons, the dendritic distri-
bution of insulin receptors shows a punctate pattern, con-
sistent with localization to synapses [20, 60]. Insulin
receptor signaling further regulates synaptic plasticity by
controlling synapse density [72]. In rodents, insulin
receptor signaling contributes to long-term memory con-
solidation and improves spatial learning [73–75]. Insulin
has also been proposed to regulate neuronal survival and to
act as a growth factor [76], possibly by activating insulin-
like growth factor (IGF) receptors [77]. An additional
possible mechanism of the protective action of insulin
could be the decrease in stress-induced hypothalamic-
pituitary-adrenal (HPA) axis activity responsiveness [78].
Interestingly, insulin also provides protection against
AbOs. Insulin has been found to block both AbO-induced
reductions in insulin receptors on dendritic surfaces [20]
and IRS-1pSer induced by AbOs [39]. Remarkably, insulin
protects synapses against AbOs [20], and the mechanism of
protection entails a decrease of AbO binding sites [20]. As
a consequence, insulin prevents the overall negative impact
of AbOs on neurons [20, 79]. Insulin further favors anti-
amyloidogenic pathways of amyloid precursor protein
processing in vitro [80]. Collectively, these studies provide
a rational basis for the use of insulin as an effective ther-
apeutic agent in AD.
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6 Intranasal Administration of Insulin: Mechanisms
and Clinical Safety Issues
Insulin has been revealed not only to control whole-body
energy and glucose homeostasis in the periphery of the
human body [81–84], but also to exert specific effects in
the CNS. Insulin receptors have been identified in a variety
of brain areas, especially in the olfactory bulb, hippocam-
pus and hypothalamus [57, 58]. One possible method for
studying the cerebral actions of insulin is via intravenous
(iv) administration. In humans, it has been shown that iv
infusions of insulin are followed by increases in CSF levels
of the hormone, indicating that plasma insulin accesses the
brain [85]. Although iv insulin has been linked to improved
memory functions in humans [86], this route of adminis-
tration possesses little therapeutic potential for the treat-
ment of CNS disorders. Intravenous application of insulin
is a highly invasive technique that leads to hypoglycemia,
which itself has detrimental effects on brain function and
thus has to be accompanied by iv glucose infusion in order
to maintain stable blood glucose levels constant in the
experimental setting. Thus, this approach is not suitable for
the treatment of CNS disorders. The approach of intranasal
delivery of neuropeptides, however, has provided us with
an alternative for the effective and rapid delivery of insulin
exclusively to the brain and thereby provides the means of
therapeutic use [22, 87].
Applying this method, insulin is sprayed into the nose of
the subject. Following intranasal application, insulin enters
the nasal mucosa and is transported extracellularly along
the axon bundles of the olfactory receptor cells in the roof
of the nasal cavity leading through the foramina of the
lamina cribrosa to the olfactory bulb, hippocampus and
other regions of the brain and upper spinal cord [21, 22,
88]. The trigeminal neural pathway has also been shown to
provide a pathway from the nasal mucosa through the
lamina cribrosa and the pons to the CNS [21, 89]. Another
proposed transport mechanisms is via the rostral migratory
stream [90].
Hence, using this intranasal delivery method, insulin
directly enters the brain, bypassing the blood-brain barrier
(BBB) [91], and can be detected in biologically relevant
concentrations in the CSF 30–40 min following intranasal
application [38]. Furthermore, these effects can be
achieved with doses that do not produce changes in
peripheral blood levels of insulin and glucose [22]. Thus,
this method selectively increases CNS insulin levels and is
therefore suitable for the investigation of both the short-
and long-term effects of insulin on the human brain without
the potential confound of peripheral side effects [92].
However, at this point it is important to state that an
intranasal dose of 40 IU insulin—as applied in many pre-
vious studies—results in short-term elevations of CSF
insulin to 25 pM levels, which is 4–10 times lower than the
insulin levels (0.1–1 nM) found to trigger brain insulin
signaling in postmortem brains [10]. Thus, future studies
are needed to show that after intranasal insulin uptake,
brain insulin levels are sufficiently raised to enhance brain
insulin signaling under in vivo conditions. Nevertheless,
many intranasal insulin studies have yielded effects on
CNS functions in humans that resembled those found in
animals after intracerebroventricular insulin administration
(e.g., reduced food intake, improved spatial memory
functions) [16, 18]. That said, we believe that the current
evidence is strong enough to support the view that intra-
nasal insulin represents a promising pharmacological
strategy to support insulin-sensitive CNS functions in
humans.
According to the existing literature, intranasal insulin
administration generally neither causes nasal irritation nor
destroys the olfactory epithelium or glomerular projections
[93, 94], and it therefore constitutes a clinically safe
application method [95] for the dissociation of central and
peripheral insulin effects.
7 Conclusion
Collectively, the presented studies present evidence for the
hypothesis that improving central nervous insulin signaling
via intranasal insulin or insulin sensitizers, which cross the
blood-brain barrier, could represent an effective way to
prevent or treat AD. However, chronic insulin treatment
can cause desensitization of insulin signaling pathways in
peripheral tissues [95], raising concerns about the long-
term efficacy of this approach. Another aspect that requires
critical consideration is that earlier studies have not shown
a beneficial effect of acute intranasal insulin administration
in AD and MCI patients carrying at least one copy of the
APOEe4 allele [28, 96]. In the most recent 4-month clinical
trial, however, positive effects of intranasally applied
insulin on AD and MCI patients carrying one or two copies
of the APOEe4 allele have been shown, whereas the opti-
mal insulin dose seems to vary between both groups [96].
Considering that the presence of one e4 allele increases the
risk of developing AD two- to threefold, while having two
e4 alleles increases the risk by about 15-fold, larger studies
of longer duration are needed to fully evaluate intranasal
insulin’s therapeutic potential in the treatment of AD.
An additional important next step for this research path
is determining the mechanism of insulin’s effects on cog-
nition. This entails answering some basic questions in
rodents and primates, e.g., which levels of extracellular
brain insulin (as opposed to CSF insulin) are actually
achieved by intranasal insulin doses that exert optimal
effects on cognition? Is an increase above baseline of
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extracellular brain insulin levels sufficient to enhance brain
insulin signaling or to normalize central nervous insulin
signaling in the case of brain insulin resistance? Does
intranasal insulin act equally with regard to neuroprotec-
tion and synaptic function? How fundamental is brain
insulin resistance to the development of both familial and
sporadic forms of AD?
While there are many open questions regarding longi-
tudinal efficacy and the mechanisms underlying its effect
on cognition, recent clinical trials support the hypothesis
that intranasal insulin may be a promising option to slow
the progress of AD [31]. With this in mind, it is not sur-
prising that intranasal administration of insulin in AD
patients was recently selected by the NIH to receive sub-
stantial funding as part of the National Alzheimer’s Plan in
the US. In this multicenter study (recruiting has not started
yet), the effects of intranasally administered insulin on
cognition, entorhinal cortex, hippocampal atrophy and CSF
biomarkers in amnestic MCI or mild AD will be examined
in a sample of 240 people (ClinicalTrials.gov Identifier:
NCT01767909). It is hypothesized that after 12 months of
treatment with intranasal insulin subjects will demonstrate
improved performance on a global measure of cognition,
on a memory composite and in daily functioning. In
addition to the examination of CSF biomarkers and hip-
pocampal and entorhinal atrophy, the study aims to
examine whether the baseline AD biomarker profile, gen-
der or APOE-e4 allele carriage predicts treatment response.
Taken together, the findings reviewed in this article
provide a strong rationale for hypothesizing that intranasal
delivery of insulin or insulin sensitizers (e.g., liraglutide)
represents a promising pharmacological strategy to support
insulin-sensitive CNS functions in humans, including hip-
pocampus-dependent memory formation and neuroprotec-
tion against AD and MCI.
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